Quantcast

Latest Protein-bound paclitaxel Stories

2009-04-20 13:08:00

Proprietary tissue proteomics platform and strategic vision for future growth in pre-clinical and clinical biomarker research spur new financing ROCKVILLE, Md., April 20 /PRNewswire/ -- Expression Pathology Inc., a leading developer of technology for tissue protein analysis, announced that it has received additional financing of $6.5 million.

2008-10-14 09:00:45

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr.

2008-10-08 09:00:51

The National Comprehensive Cancer Network, Abraxis BioScience and AstraZeneca have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anticancer drug Abraxane for injectable suspension, which is based on the company's proprietary tumor targeting technology known as the nab platform.

2008-10-08 09:00:36

Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (Nasdaq: ABII), and TorreyPines Therapeutics, Inc.

2008-10-07 09:00:14

The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.

2008-07-18 09:01:12

Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

2008-07-18 09:00:20

Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.

2008-07-14 12:00:20

Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.